Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy for neoplasia treatment

Inactive Publication Date: 2014-09-11
BOEHRINGER INGELHEIM INT GMBH
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new treatment for prostate neoplasia (including benign prostatic hyperplasia and prostate cancer) using an insulin-like growth factor (IGF) receptor antagonist. The treatment can be used alone or in combination with an androgen receptor antagonist. The method involves administering the IGF receptor antagonist and the androgen receptor antagonist to a patient on the same day or on different days. The technical effect of this invention is an improved treatment approach for prostate neoplasia that targets the IGF receptor pathway and the androgen receptor pathway simultaneously, leading to enhanced therapeutic efficacy and reduced risk of side effects.

Problems solved by technology

Castration-resistant prostate cancer has been shown to be sensitive, but not resistant, to sustained manipulation of the androgen / AR axis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for neoplasia treatment
  • Combination therapy for neoplasia treatment
  • Combination therapy for neoplasia treatment

Examples

Experimental program
Comparison scheme
Effect test

example 1

Inhibitory Effect of IGF and AR Signaling Blockade on Prostate Cancer Cell Proliferation

[0096]In order to test the anti-proliferative effects of the combination of AR and IGF-1 / 2 inhibition, 10 different prostate cancer cell lines (Bob, C4-2, C-4-2B, DUCaP, MDA PCa 2b, P4E6, PC-3, Shmac 4, Shmac 5, VCaP) were treated with the AR antagonist MDV-3100 and fully human monoclonal antibodies against the IGF ligands (IGF mAb—1 and IGF mAb—2), as single agents and in combination, in 2D cell proliferation assays (Table 1). Three of the tested cell lines (VCaP and DUCaP—both cell lines were derived from the same prostate cancer patient from different sites of metastasis, and MDA PCa 2b) showed single agent anti-proliferative response to both the AR and IGF signaling inhibition alone, and an enhanced effect when combined (FIG. 1).

example 2

Inhibitory Effect of IGF Signaling and Androgen Synthesis Blockade on Prostate Cancer Cell Proliferation

[0097]As a second approach to test the combination potential of androgen and IGF signaling inhibition, 8 different prostate cancer cell lines (22Rv1, BM 1604, DU-145, DUCaP, LNCaP, MDA PCa 2b, PC-3, VCaP) were treated with abiraterone acetate, which selectively inhibits CYP17A and thus de novo synthesis of androgens, alone and in combination with IGF-ligand neutralizing monoclonal antibodies (IGF mAb—1 and IGF mAb—2). The results from these assays also identified VCaP, MDA PCa 2b, and DUCaP cells to be the only cell lines which are responsive to both single agent and combination treatments. Treatment with abiraterone acetate, however, implies autocrine androgen production by the tumor cells for abiraterone acetate to show anti-proliferative effects. This might limit the number of cells sensitive to abiraterone acetate treatment. Results of 2D and 3D proliferation assays for VCaP a...

example 3

The Presence of Androgen Receptor and IGF-1R as Well as Expression of PTEN and Wt PIK3CA Characterizes Prostate Cancer Cells Sensitive to the Combination of Androgen and IGF Signaling Inhibitors

[0098]FIG. 3 shows signaling protein expression in the VCaP, MDA PCa 2b, and DUCaP cell lines, which are sensitive to AR and IGF signaling inhibition, in comparison to the insensitive cell line PC-3. Cells were treated with MDV-3100 and IGF mAb—1 as single agents, or in combination, for 24 hours and protein lysates were compared to untreated controls for protein expression of IGF-1R, AR, PTEN and AKT, and for phosphorylation of AKT-Ser473. Responsive cell lines expressed wt AR, IGF-1R, and PTEN. These characteristics were not present in PC-3 or the other tested cell lines which did not show an anti-proliferative response to either one of the single agent treatments or the combination of both agents (Table 1).

[0099]These results indicate that in the presence of androgen receptor, IGF-1R, and e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.

Description

[0001]The present invention relates to the pharmaceutical treatment of neoplasia, including benign and malignant tumors.BACKGROUND OF THE INVENTION[0002]Prostate cancer is the most common malignancy diagnosed in males and a leading cause of mortality in western countries (American Cancer Society, 2010 (http: / / www.cancer.org / acs / groups / content / ©epidemiologysurveilance / documents / document / acspc-026238.pdf)). Androgens and stimulation of their receptor, androgen receptor (AR), are essential for the development and function of the normal prostate gland, and the development and progression of prostate cancer (reviewed in Basu S et al., Horm Cancer. 2010 October; 1(5):223-8.; Yadav N et al., Minerva Urol Nefrol. 2012 March; 64(1):35-49). For metastatic prostate cancer, androgen deprivation therapy remains the standard treatment. Despite the fact that initially more than 90% of patients respond to androgen deprivation therapy, the clinical benefits are temporary with tumors becoming refract...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28A61K39/395A61K45/06A61K31/4166
CPCC07K16/2863A61K45/06A61K39/3955A61K31/4166A61K31/00A61K31/4164A61K39/39558A61K2039/505A61P5/06A61P5/26A61P5/28A61P5/30A61P5/40A61P5/44A61P5/48A61P13/08A61P35/00A61P43/00C07K16/22A61K2300/00
Inventor ADAM, PAULFRIEDBICHLER, KATRIN
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com